ArticleInflammatory bowel diseases2016
Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease.
Article in Inflammatory bowel diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Effects of Age on Inflammatory Bowel Disease Presentation and Management in Older Adults.Digestive diseases and sciences · 2026Review
- Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort.Inflammatory bowel diseases · 2026Observational
- Existential Reflections by Older Adults With Inflammatory Bowel Diseases on Medical and Surgical Treatments.The American journal of gastroenterology · 2025Article
- Frailty: An Underappreciated Risk Factor for IBD Complications.Current gastroenterology reports · 2024Review
- Considerations on Multimorbidity and Frailty in Inflammatory Bowel Diseases.Journal of Crohn's & colitis · 2024Review
- Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Article
- Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients.World journal of gastroenterology · 2023Review
- Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks?Drugs & aging · 2022Review
- The 5Ms of Geriatrics in Gastroenterology: The Path to Creating Age-Friendly Care for Older Adults With Inflammatory Bowel Diseases and Cirrhosis.Clinical and translational gastroenterology · 2022Article
- Understanding clinician connections to inform efforts to promote high-quality inflammatory bowel disease care.PloS one · 2022Article
- Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD.Journal of the Canadian Association of Gastroenterology · 2021Article
- Challenges and Opportunities in Social Media Research in Gastroenterology.Digestive diseases and sciences · 2021Article
- Tryptophan-kynurenine metabolism: a link between the gut and brain for depression in inflammatory bowel disease.Journal of neuroinflammation · 2021Review
- Frailty in inflammatory bowel diseases: an emerging concept.Therapeutic advances in gastroenterology · 2021Review
- Correlation of Patient-Reported Outcome (PRO-2) with Endoscopic and Histological Features in Ulcerative Colitis and Crohn's Disease Patients.Gastroenterology research and practice · 2020Article
- Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape.World journal of gastroenterology · 2019Review
- Inflammatory Bowel Disease is Similar in Patients with Older Onset and Younger Onset.Inflammatory bowel diseases · 2017Observational
- Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.Inflammatory bowel diseases · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundOlder individuals with inflammatory bowel disease (IBD) require ongoing medications. We aimed to describe (1) medication use in older and younger IBD patients and (2) medication associations with patient reported outcomes (PROs) in older patients.
methodsWe conducted cross-sectional and longitudinal analyses within CCFA Partners internet-based cohort of patients with self-reported IBD. We assessed medication use by disease sub-type and age. We used bivariate analyses to (1) compare medication use in older and younger patients and (2) determine associations between continued steroid use and patient reported outcomes in older patients.
resultsWe included 5382 participants with IBD; 1004 were older (≥age 60). Older patients with Crohn's disease (CD) had lower antitumor necrosis factor alpha (anti-TNF) use at baseline (29.1% versus 44.3%, P < 0.001), comparable steroid use (16.0% versus 16.5%, P = 0.77), and higher aminosalicylate use (40.3% versus 33.9%, P = 0.003) versus younger patients. Older ulcerative colitis (UC) patients had similar anti-TNF use (16.0% versus 19.2%, P = 0.16), lower steroid use (9.6% versus 15.4%, P = 0.004), and higher aminosalicylate use (73.8% versus 68.2%, P = 0.04) at baseline. In longitudinal analyses, older CD patients had higher continued steroid use (11.6% versus 7.8%, P = 0.002); which was associated with worsened anxiety (P = 0.02), sleep (P = 0.01), and fatigue (P = 0.001) versus nonuse. Older CD patients on steroids, versus anti-TNF or immunomodulators, had increased depression (P = 0.04) and anxiety (P = 0.03).
conclusionsMedication utilization differs in older patients with IBD. Older CD patients have higher continued steroid use associated with worsened patient reported outcomes. As in younger IBD populations, continued steroid use should be limited in older patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.